Genetic polymorphisms of DPYD in patients with breast cancer on capecitabine therapy
DOI:
https://doi.org/10.22317/jcms.v9i3.1350Keywords:
Ca15.3, Breast Neoplasms, Estradiol, Capecitabine, polymorphismAbstract
Objectives: Breast cancer is the primary cause of death in Iraqi women aged 30–54 years. The study examined the relationship between (G > A) (rs3918290) and (rs55886062, T >G) DPYD gene polymorphisms, their haplotypes, and capecitabine serum concentrations in postmenopausal Iraqi women with breast cancer in postmenopausal women. During capecitabine chemotherapy.
Methods: The study included 200 women: 100 apparently health (45-75 years old) and 100 with breast cancer (40-70 years old). This study, conducted between July and October 2022 at the oncology centre at Imam al-Hussain medical city in Kerbala, Iraq, plasma levels of Capacetabine and 5fu were measured in breast cancer patients who had been taking capecitabine for at least three months. All participants gave informed consent.
Results: Capecitabine, and 5FU concentrations in breast cancer patients differed significantly, As the results showed, Capecitabine, and 5FU had a significantly higher concentration of them in patients with the TT allele than in those with the CC and CT alleles for the polymorphism (IVS14 + 1G > A) (rs3918290) and in patients with DPYD*13 (rs55886062) with the CC allele rather than the AA and AC alleles. Mutant allele carriers had increased Capecitabine concentrations (p<0.001).
Conclusion: Ca15.3, serum calcium, and estradiol all exist in bodily serum, making them a potentially useful novel diagnostic biomarker for patients with breast cancer due to their high levels of stability, as well as the biological properties of tumors, such as serum calcium and estrogen.
References
Parkins, K. M., Dubois, V. P., Hamilton, A. M., Makela, A. V., Ronald, J. A., & Foster, P. J. (2018). Multimodality cellular and molecular imaging of concomitant tumour enhancement in a syngeneic mouse model of breast cancer metastasis. Scientific Reports, 8(1), 8930.
Alwan, N. A. (2016). Breast cancer among Iraqi women: Preliminary findings from a regional comparative Breast Cancer Research Project. Journal of Global Oncology, 2(5), 255.
Chen, Z., Xu, L., Shi, W., Zeng, F., Zhuo, R., Hao, X., & Fan, P. (2020). Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017. Breast Cancer Research and Treatment, 180, 481–490.
Rasool, A., Bunterngchit, C., Tiejian, L., Islam, M. R., Qu, Q., & Jiang, Q. (2022). Improved machine learning-based predictive models for breast cancer diagnosis. International Journal of Environmental Research and Public Health, 19(6), 3211.
Moo, T. A., Sanford, R., Dang, C., & Morrow, M. (2018). Overview of breast cancer therapy. PET Clinics, 13(3), 339–354.
Alqahtani, S., Alzaidi, R., Alsultan, A., Asiri, A., Asiri, Y., & Alsaleh, K. (2022). Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients. Saudi Pharmaceutical Journal, 30(5), 527–531.
Jurczyk, M., Król, M., Midro, A., Kurnik-Łucka, M., Poniatowski, A., & Gil, K. (2021). Cardiotoxicity of fluoropyrimidines: Epidemiology, mechanisms, diagnosis, and management. Journal of Clinical Medicine, 10(19), 4426.
Sharma, V., Gupta, S. K., & Verma, M. (2019). Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemotherapy and Pharmacology, 84(6), 1157–1166.
Piórkowska, E., Kaza, M., Fitatiuk, J., Szlaska, I., Pawiński, T., & Rudzki, P. J. (2014). Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 69(7), 500–505.
Zhu, L., Shen, G. J., Ding, S. Q., & Hua, X. I. N. (2012). Determination of 5-fluorouracil in 5-fluorouracil injection and human serum by HPLC. Journal of Food and Drug Analysis, 20(4), 15.
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., ... & Winer, E. P. (2020). Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. New England Journal of Medicine, 382(7), 597–609.
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2021). Small molecule kinase inhibitor drugs (1995–2021): Medical indication, pharmacology, and synthesis. Journal of Medicinal Chemistry, 65(2), 1047–1131.
Niehoff, N. M., Nichols, H. B., Zhao, S., White, A. J., & Sandler, D. P. (2019). Adult physical activity and breast cancer risk in women with a family history of breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 28(1), 51–58.
Han, L., Zhu, Y., Liu, Z., Yu, T., He, C., Jiang, W., ... & Luo, Y. (2019). Radiomic nomogram for prediction of axillary lymph node metastasis in breast cancer. European Radiology, 29, 3820–3829.
Calì Cassi, L., Vanni, G., Petrella, G., Orsaria, P., Pistolese, C., Lo Russo, G., ... & Buonomo, O. (2016). Comparative study of oncoplastic versus nononcoplastic breast conserving surgery in a group of 211 breast cancer patients. European Review for Medical and Pharmacological Sciences, 20(14), 2950–2954.
Moey, S. F., Sowtali, S. N., Mohamad Ismail, M. F., Hashi, A. A., & Che Mohamed, N. (2022). Cultural, Religious and Socio-Ethical Misconceptions among Muslim Women towards Breast Cancer Screening: A Systematic Review. Asian Pacific Journal of Cancer Prevention, 23(12), 3971–3982.
Koto, M. Z., Becker, J. H. R., Mokone-Fatunla, D. H., Mundawarara, S., & Bondo, M. (2019). Laterality of breast cancer at Dr George Mukhari academic hospital. South African Journal of Surgery, 57(3), 55–61.
Kruk, J. (2012). Self-reported psychological stress and the risk of breast cancer: A case-control study. Stress, 15(2), 162–171.
Melchior, M., Goldberg, M., Krieger, N., Kawachi, I., Menvielle, G., Zins, M., & Berkman, L. F. (2005). Occupational class, occupational mobility and cancer incidence among middle-aged men and women: A prospective study of the French GAZEL cohort. Cancer Causes & Control, 16, 515–524.
Hassan, M. S. U., Ansari, J., Spooner, D., & Hussain, S. A. (2010). Chemotherapy for breast cancer. Oncology Reports, 24(5), 1121–1131.
Hu, N., Si, Y., Yue, J., Sun, T., Wang, X., Jia, Z., ... & Yuan, P. (2021). Anlotinib has good efficacy and low toxicity: A phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. Cancer Biology & Medicine, 18(3), 849.
. Oliveira, M., Saura, C., Nuciforo, P., Calvo, I., Andersen, J., Passos-Coelho, J. L., ... & Isakoff, S. J. (2019). FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Annals of Oncology, 30(8), 1289–1297.
Lunenburg CA, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJ, Mulder H, Rongen GA, van Schaik RH, van der Weide J. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. European Journal of Human Genetics. 2020 Apr;28(4):508-17.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
